Regulation of Hematopoietic Cell Development and Function Through Phosphoinositides
Open Access
- 4 May 2018
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 9, 931
- https://doi.org/10.3389/fimmu.2018.00931
Abstract
One of the most paramount receptor-induced signal transduction mechanisms in hematopoietic cells is production of the lipid second messenger phosphatidylinositol(3,4,5) trisphosphate (PIP3) by class I phosphoinositide 3 kinases (PI3K). Defective PIP3 signaling impairs almost every aspect of hematopoiesis, including T cell development and function. Limiting PIP3 signaling is particularly important, because excessive PIP3 function in lymphocytes can transform them and cause blood cancers. Here, we review the key functions of PIP3 and related phosphoinositides in hematopoietic cells, with a special focus on those mechanisms dampening PIP3 production, turnover, or function. Recent studies have shown that beyond "canonical" turnover by the PIP3 phosphatases and tumor suppressors phosphatase and tensin homolog (PTEN) and SH2 domain-containing inositol-5-phosphatase-1 (SHIP-1/2), PIP3 function in hematopoietic cells can also be dampened through antagonism with the soluble PIP3 analogs inositol(1,3,4,5) tetrakisphosphate (IP4) and inositol-heptakisphosphate (IP7). Other evidence suggests that IP4 can promote PIP3 function in thymocytes. Moreover, IP4 or the kinases producing it limit store-operated Ca2+ entry through Orai channels in B cells, T cells, and neutrophils to control cell survival and function. We discuss current models for how soluble inositol phosphates can have such diverse functions and can govern as distinct processes as hematopoietic stem cell homeostasis, neutrophil macrophage and NK cell function, and development and function of B cells and T cells. Finally, we will review the pathological consequences of dysregulated IP4 activity in immune cells and highlight contributions of impaired inositol phosphate functions in disorders such as Kawasaki disease, common variable immunodeficiency, or blood cancer.Keywords
Funding Information
- National Institutes of Health (AI070845, GM100785, GM065230)
- Leukemia and Lymphoma Society (1440-11)
- Scripps Research Institute
This publication has 192 references indexed in Scilit:
- Inositol hexakisphosphate kinase 1 regulates neutrophil function in innate immunity by inhibiting phosphatidylinositol-(3,4,5)-trisphosphate signalingNature Immunology, 2011
- Tonic BCR signaling represses receptor editing via Raf- and calcium-dependent signaling pathwaysImmunology Letters, 2011
- Inositol Pyrophosphates Inhibit Akt Signaling, Thereby Regulating Insulin Sensitivity and Weight GainCell, 2010
- Proline Isomerization Preorganizes the Itk SH2 Domain for Binding to the Itk SH3 DomainJournal of Molecular Biology, 2009
- The Immunological Genome Project: networks of gene expression in immune cellsNature Immunology, 2008
- Large-Scale Mutagenesis in p19ARF- and p53-Deficient Mice Identifies Cancer Genes and Their Collaborative NetworksCell, 2008
- Critical roles of the PI3K/Akt signaling pathway in T cell developmentImmunology Letters, 2008
- ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysmsNature Genetics, 2007
- Inositol 1,3,4,5-Tetrakisphosphate Negatively Regulates Phosphatidylinositol-3,4,5- Trisphosphate Signaling in NeutrophilsImmunity, 2007
- The regulation and function of inositol 1,4,5-trisphosphate 3-kinasesAdvances in Enzyme Regulation, 2006